Reviva Pharmaceuticals Holdings Inc (RVPH)

May 13, 2025

Reviva to Participate in the A.G.P. Healthcare Company Showcase - GlobeNewswire

May 13, 2025

May 13, 2025

Tower Research Capital LLC TRC Has $48,000 Stock Holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World

May 13, 2025

May 11, 2025

Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025

May 04, 2025

Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Grows By 30.5% - Defense World

May 04, 2025

May 03, 2025

Geode Capital Management LLC Grows Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World

May 03, 2025

May 01, 2025

Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.

May 01, 2025

Apr 29, 2025

Reviva to Participate in the Citizens Life Sciences Conference - GlobeNewswire

Apr 29, 2025

Apr 29, 2025

Reviva Pharma CEO Takes Center Stage: Key Updates Coming at Major Life Sciences Conference - Stock Titan

Apr 29, 2025

Apr 28, 2025

Gaining Ground: Reviva Pharmaceuticals Holdings Inc (RVPH) Closes Lower at 0.86, Down -4.98 - DWinneX

Apr 28, 2025

Apr 28, 2025

Market Update: American Rebel Holdings Inc (AREB) Sees Negative Movement, Closing at 3.85 - DWinneX

Apr 28, 2025

Apr 27, 2025

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire

Apr 27, 2025

Apr 26, 2025

D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World

Apr 26, 2025

Apr 24, 2025

Reviva Pharmaceuticals Holdings Inc Inc. (RVPH) Price Performance: The Role of Supply and Demand - investchronicle.com

Apr 24, 2025

Apr 24, 2025

Reviva to Present Late-Breaking Poster on the RECOVER - GlobeNewswire

Apr 24, 2025

Apr 24, 2025

Major Phase 3 Breakthrough: Reviva Unveils 12-Month Schizophrenia Treatment Data at ASCP 2025 - Stock Titan

Apr 24, 2025

Apr 24, 2025

Investing in Reviva Pharmaceuticals Holdings Inc (RVPH) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com

Apr 24, 2025

Apr 21, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 21, 2025

Apr 19, 2025

Reviva Pharmaceuticals (RVPH) to Release Earnings on Monday - Defense World

Apr 19, 2025

Apr 07, 2025

RVPH: M&A Deals Highlight Brilaroxazine Value - MSN

Apr 07, 2025

Apr 07, 2025

What is Roth Capital’s Forecast for RVPH Q1 Earnings? - Defense World

Apr 07, 2025

Apr 04, 2025

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com

Apr 04, 2025

Apr 03, 2025

Reviva Pharmaceuticals Holdings Inc. (RVPH) reports earnings - qz.com

Apr 03, 2025

Apr 02, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital - Defense World

Apr 02, 2025

Apr 02, 2025

Reviva Pharmaceuticals Reports 2024 Financial Results - TipRanks

Apr 02, 2025

Apr 01, 2025

RVPH stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Apr 01, 2025

Mar 31, 2025

Reviva Pharmaceuticals Delays Annual Report Filing - TipRanks

Mar 31, 2025

Mar 31, 2025

Reviva Pharmaceuticals Holdings Files For Non-Timely 10-KSEC Filing - MarketScreener

Mar 31, 2025

Mar 31, 2025

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Mar 31, 2025

Mar 31, 2025

Breakthrough: Reviva's Schizophrenia Treatment Delivers Powerful 1-Year Results, Losses Narrow - Stock Titan

Mar 31, 2025

Mar 30, 2025

Reviva to Present Brilaroxazine Topline Data for Long-Term - GlobeNewswire

Mar 30, 2025

Mar 30, 2025

Major Clinical Data: 52-Week Results for New Schizophrenia Drug Coming at SIRS 2025 - Stock Titan

Mar 30, 2025

Mar 27, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Down 3.5% – What’s Next? - Defense World

Mar 27, 2025

Mar 07, 2025

Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR.com

Mar 07, 2025

Mar 02, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Buy” from Brokerages - Defense World

Mar 02, 2025

Feb 18, 2025

Reviva Pharmaceuticals adjusts executive pay, grants stock options By Investing.com - Investing.com South Africa

Feb 18, 2025

Feb 18, 2025

Reviva Pharmaceuticals adjusts executive pay, grants stock options - Investing.com India

Feb 18, 2025

Feb 18, 2025

Reviva Pharmaceuticals Approves Executive Compensation Changes - TipRanks

Feb 18, 2025

Feb 12, 2025

Unusually active option classes on open February 12th - TipRanks

Feb 12, 2025

Feb 10, 2025

Get in on Reviva Pharmaceuticals Holdings Inc’s (RVPH) buy-in window today! - SETE News

Feb 10, 2025

Feb 08, 2025

Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.40 - MarketBeat

Feb 08, 2025

Feb 06, 2025

Adversity is less terrifying than hope: Reviva Pharmaceuticals Holdings Inc (RVPH) - SETE News

Feb 06, 2025

Feb 05, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts - Defense World

Feb 05, 2025

Feb 05, 2025

How should investors view Reviva Pharmaceuticals Holdings Inc (RVPH)? - US Post News

Feb 05, 2025

Feb 04, 2025

Reviva Pharmaceuticals Holdings Inc (RVPH) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Feb 04, 2025

Feb 04, 2025

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com

Feb 04, 2025